Ellard G A
Department of Medical Microbiology, St. George's Hospital Medical School, London, UK.
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S343-6; discussion S351-2.
The perceived need to demonstrate whether or not the actual amounts of rifampicin, isoniazid and pyrazinamide in fixed-dose combination tablets or capsules correspond to their stated drug contents.
To adapt specific, robust and simple colorimetric methods that have been previously applied to measuring plasma and urinary rifampicin, isoniazid, pyrazinamide and ethambutol concentrations to estimate tablet and capsule drug contents.
The methods were applied to the analysis of 14 commercially manufactured fixed-dose combinations: two capsule and three tablet formulations containing rifampicin and isoniazid; seven tablet formulations containing rifampicin, isoniazid and pyrazinamide; and two tablet formulations containing rifampicin, isoniazid, pyrazinamide and ethambutol.
All the combined formulations contained near to their stated drug contents. Replicate analyses confirmed the excellent precision of the drug analyses.
Such methods are not only rapid to perform but should be practical in many Third World situations with relatively modest laboratory facilities.
人们认为有必要证明固定剂量复方片剂或胶囊中利福平、异烟肼和吡嗪酰胺的实际含量是否与其标明的药物含量相符。
采用先前用于测量血浆和尿液中利福平、异烟肼、吡嗪酰胺和乙胺丁醇浓度的特定、可靠且简单的比色法,来估算片剂和胶囊中的药物含量。
将这些方法应用于分析14种商业生产的固定剂量复方制剂:两种含利福平和异烟肼的胶囊制剂以及三种片剂制剂;七种含利福平、异烟肼和吡嗪酰胺的片剂制剂;以及两种含利福平、异烟肼、吡嗪酰胺和乙胺丁醇的片剂制剂。
所有复方制剂的药物含量均接近其标明的含量。重复分析证实了药物分析具有极高的精密度。
此类方法不仅操作快速,而且在许多实验室设施相对简陋的第三世界国家的实际应用中也应具有可行性。